Adaptimmune Therapeutics (NASDAQ:ADAP) target price raised to $16.00, reported today by Raymond James
- Updated: September 30, 2016
Adaptimmune Therapeutics (NASDAQ:ADAP) had its target price raised to $16.00 by Raymond James in a report released 9/30/2016. The new target price indicates a possible upside of 1.23% based on the company's last stock close price.
Previously on 3/29/2016, Leerink Swann reported about Adaptimmune Therapeutics (NASDAQ:ADAP) lowered the target price from $24.00 to $23.00. At the time, this indicated a possible upside of 1.98%.
Yesterday Adaptimmune Therapeutics (NASDAQ:ADAP) traded 4.17% higher at $7.19. The company’s 50-day moving average is $7.18 and its 200-day moving average is $8.47. The last stock close price is down -11.62% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 333,449 shares of the stock were exchanged, up from an average trading volume of 124,945
See Chart Below
Adaptimmune Therapeutics has a 52 week low of $6.19 and a 52 week high of $14.78 The company’s market cap is currently $0.
About Adaptimmune Therapeutics (NASDAQ:ADAP)
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company's TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.